Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

TenNor Therapeutics Raises $71M in Hong Kong IPO – Antimicrobial Pipeline Targets H. pylori and Implant-Associated Infections

Fineline Cube May 14, 2026
Company Deals Drug

Fosun Pharma Secures Global Rights to AriBio’s Alzheimer’s Drug AR1001 in $240M Deal – PDE-5 Inhibitor Shows Promise in Phase III

Fineline Cube May 14, 2026
Company Deals

Merck & Co. Forges Four Strategic Partnerships with Chinese Biotechs to Advance Autoimmune and Oncology Pipeline Through MCICC Platform

Fineline Cube May 14, 2026
Company Deals

Shanghai Immunocan Biotech Secures RMB 250M Series A Led by Vivo Capital to Advance Gene-Edited Antibody Discovery Platforms

Fineline Cube May 13, 2026
Company Deals

Shenzhen Weiguang Biological to Raise RMB 1.5B in Private Placement to Fund Smart Industrial Base Expansion

Fineline Cube May 13, 2026
Policy / Regulatory

China’s CDE Reports Record Drug Review Activity in 2025 – Breakthrough Therapy Designations Surge 11% as Regulatory Filings Hit 20,149

Fineline Cube May 14, 2026
Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Fineline Cube May 14, 2026
Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Fineline Cube May 14, 2026
Company Drug

3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients

Fineline Cube Jul 29, 2024

3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...

Company Drug

CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment

Fineline Cube Jul 29, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...

Company Drug

Alphamab’s KN057 Earns FDA Orphan Drug Designation for Hemophilia B Treatment

Fineline Cube Jul 29, 2024

Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has received another orphan drug...

Company Drug

Junshi Biosciences’ Toripalimab Recommended for EU Approval for Two Indications

Fineline Cube Jul 29, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has been recommended for approval by...

Company Drug

Akeso Biopharma’s Ivonescimab NDA Accepted by NMPA, Strengthening NSCLC Treatment Options

Fineline Cube Jul 29, 2024

Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has received a significant boost...

Company Medical Device

Beijing Balance Medical Secures NMPA Nod for Pioneering Heart Valve Patch

Fineline Cube Jul 29, 2024

Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology firm based in...

Company Drug

Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight

Fineline Cube Jul 29, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...

Company Medical Device

MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA

Fineline Cube Jul 29, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...

Company Drug

Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment

Fineline Cube Jul 29, 2024

Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...

Policy / Regulatory

China Unveils Comprehensive 2030 Plan to Combat Diabetes

Fineline Cube Jul 29, 2024

China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...

Company Deals R&D

CNBG and University of Macau Ink Deal to Establish Joint Biotech Lab

Fineline Cube Jul 29, 2024

China National Biotec Group Company Ltd (CNBG) has announced a strategic collaboration with the University...

Company Deals

Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge

Fineline Cube Jul 26, 2024

Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the...

Company Deals

Shanghai Escugen Partners with Innolake Biopharma to Develop Novel ADCs Using EZWi-Fit Platfo

Fineline Cube Jul 26, 2024

Shanghai Escugen, a Chinese biopharmaceutical company, has entered into a strategic partnership with fellow Chinese...

Company Drug

Belief BioMed’s Hemophilia B Gene Therapy BBM-H901 Slated for Priority Review in China

Fineline Cube Jul 26, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that the market application...

Policy / Regulatory

NHSA Report: China’s Medical Insurance Fund Records Significant Growth and Savings in 2023

Fineline Cube Jul 26, 2024

The National Healthcare Security Administration (NHSA) has released its comprehensive annual statistical report for the...

Company Deals R&D

CanSino Biologics Partners with Malaysia’s NIBM to Develop mRNA Influenza Vaccine

Fineline Cube Jul 26, 2024

CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic...

Company Deals

Shanghai’s Spectrum Dynamics Medical Secures Major Financing for Molecular Imaging Innovations

Fineline Cube Jul 26, 2024

Spectrum Dynamics Medical, a Shanghai-based specialist in medical molecular imaging, has reportedly secured hundreds of...

Company Deals

Shanghai GenTech Expands into Life Sciences with Acquisition of Konosai Biotechnology

Fineline Cube Jul 26, 2024

Shanghai GenTech Co., Ltd., a Chinese solutions provider with expertise in flat panel display, LED,...

Company Deals

Innovent Biologics Partners with Wecomput Technology to Accelerate AI in Drug Development

Fineline Cube Jul 26, 2024

Innovent Biologics Inc. (Innovent) (HKG: 1801), a leading biopharmaceutical company based in China, has entered...

Company Deals

United Imaging Healthcare Invests RMB 120 Million in Particle Accelerator Specialist Long Beam Technology

Fineline Cube Jul 26, 2024

United Imaging Healthcare (UIH, SHA: 688271), a leading medical device company in China, has announced...

Posts pagination

1 … 323 324 325 … 666

Recent updates

  • Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors
  • Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad
  • Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement
  • Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors
  • Takeda Reports $28.5B Revenue in FY2025 Despite Vyvanse Patent Cliff – 78% Net Profit Surge Amid $1.26B Restructuring Plan
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hansoh Pharma Receives NMPA Approval for HS-10541 Phase I Trial – Category 1 KRAS G12C Inhibitor Targets Advanced Solid Tumors

Company Medical Device

Basecare Medical Device Secures NMPA Approval for Gems Embryo Culture Medium – Chinese IVF Specialist Completes Global Regulatory Triad

Company Drug

Pfizer’s Hympavzi Gains European Approval for Hemophilia with Inhibitors – Novel TFPI-Targeting Therapy Offers Weekly Subcutaneous Alternative to Factor Replacement

Company Drug

Henlius Biotech Secures Australian TGA Approval for HLX48 Phase I Trial – Novel EGFR/c-Met Bispecific ADC Targets Advanced Solid Tumors

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.